Professional Biography

Viola T. Kung, Ph.D. Partner

  • Palo Alto

    D +1.650.838.4457

    F +1.650.838.4657

    Palo Alto

    3150 Porter Drive

    Palo Alto, CA

    +1.650.838.4457

    VKung@perkinscoie.com

  • Taipei

    T +886.2.8101.2031

    F +886.2.8101.2038

    Taipei

    Taipei 101 Tower, Suite F, 45th Floor, No. 7, Sec. 5, Xinyi Road

    +886.2.8101.2031

    VKung@perkinscoie.com

loader

OVERVIEW

Viola Kung is a partner in the firm's Patent Procurement practice focusing on patent prosecution and patent counseling in the chemical, pharmaceutical, diagnostics, biotechnology and small molecule arenas, including methods for treating inflammatory diseases, ophthalmic diseases, neurological diseases, neuropsychiatric diseases, pulmonary diseases, autoimmune diseases, and pain; pharmaceutical formulations, chemical formulations, new chemical entity, chemical processes, medical devices, nucleotide derivatives, monoclonal antibodies, in vitro diagnostics, immunoassays, gene expression, antisense, RNA transformation vectors, recombinant viral nucleic acids, DNA sequencing, tumor suppressor genes, fusion proteins, interferons, electrophoretic displays, silica filter media, sol gels, and carbon nanotubes. Viola is experienced in reexamination, appeal, and interference proceedings before the U.S. Patent and Trademark Office. Her other client counseling activities include opinion work, freedom-to-operate and due diligence evaluation.

Through her extensive research and industrial training as a development director and as a research scientist, Viola has broad R&D experience in formulation, assay development, in vitro diagnostics, protein and DNA interaction, lipid bilayer membrane, conjugation chemistry and molecular biology.

She is an inventor of a total of 21 US patents in the areas of immunoassay methods and kits; kinetic microtiter plate readers, heptane derivatized membrane, DNA detection methods; DNA-protein separation methods; liposome formulations, protein conjugation, bone resorption, and biotin reagents. Viola also has numerous publications in scientific journals.

Representative Matters

  • U.8. Patent  8,492,139.  Detection system for high sensitivity fluorescent assays. This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area and a high molecular weight polymer having multiple binding molecules and multiple fluorescent labels.
  • U.S. Patent 8,476,316.  3-methanesulfonylpropionitrile for treating inflammation and pain.  This invention is in clinical trial for treating osteoarthritis.   The invention is directed to purified 3-methanesulfonylpropionitrile and a pharmaceutical composition comprising the purified compound. The invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain. 
  • U.S. Patent 8,299,096.  Method for treating pulmonary diseases using rho kinase inhibitor compounds. This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.
  • U.S. Patent 8,188,076.  Compositions, synthesis, and methods of utilizing arylpiperazine derivatives.  This invention is in clinical trial for treating schizophrenia.  This invention provides arylpiperazine derivatives having Formula I which can be used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.
  • U.S. Patent  8,007,813.  CD95-Fc fusion proteins.  This invention is directed to a fusion protein comprising (i) one first domain comprising a ligand binding domain of the CD95 receptor fused to (ii) a second domain comprising a portion of a constant immunoglobulin domain.
  • U.S. Patent  7,977,307.  Method for reducing pain with ziconotide and morphine.  This invention is directed to a method for reducing pain in a human patient by administering ziconotide and morphine by continuous intrathecal infusion.
  • U.S. Patent  7,947,850.  Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones.  This invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The compounds are useful in the synthesis and manufacture of latrunculins, which are useful for treating diseases or conditions associated with inhibiting actin polymerization.
  • U.S. Patent 7,850,012. Silane-treated silica filter media. This invention is directed to silane-treated silica filter media prepared by reacting the surface silanol group of silica filter media with specific silanes.
  • U.S. Patent 7,425,617. Antibodies to the cell cycle regulatory protein p16. This application prevailed in an Interference Proceeding. This invention relates a family of cell-cycle regulatory proteins which function as an inhibitor of cell-cycle progression and cell growth. This invention is directed to antibodies specifically immunoreactive with p16 protein.
  • U.S. Patent 7,378,082. Method for treating allergic rhinitis without adverse effects. This application was filed as an accelerated application, and was issued within six months.  This invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation containing epinastine as an active ingredient.
  • U.S. Patent 7,371,585. Membranes incorporating recognition moieties. The invention provides a thiosulfonate-activated ionophore comprising an ionophore, a spacer group, and an alkylthiosulfonate moiety. The invention also provides a conjugate comprising an ionophore, a spacer group, and a recognition molecule. The invention further provides membranes incorporating the conjugates and biosensors comprising said membranes.
  • U.S. Patent 7,267,825. Parvovirus vectors and their use. This invention relates to a parvovirus vector having a parvovirus DNA excisable from the vector DNA in a parvovirus-permissive cell.
  • United States Patent 7,053,220. Hydroxyalkanoyl aminopyrazoles and Hydroxyalkanoyl aminopyrazoles and related compounds. This invention is directed to a class of compounds including hydroxyalkanoyl amino pyrazoles, which are useful in the prevention and treatment of Alzheimer's disease. 
  • U.S. Patent 7,038,670.  Electrophoretic display with dual mode switching. The invention relates to an improved EPD which comprises both the traditional up/down switching and the in-planeswitching modes.
  • U.S. Patent 6,602,695. DNA polymerase mutant having one or more mutations in the active site. This invention provides a DNA polymerase that is a mutant form of a naturally occurring DNA polymerase, of which one or more amino acids in the active site are mutated.
  • U.S. Patent 6,376,752.  Cytoplasmic inhibition of gene expression in a plant. The invention provides genetic constructions for the expression of inhibitory RNA in the cytoplasm of plant cells. The inhibitory RNA may be an anti-sense RNA or a co-suppressor RNA.
MORE LESS

Professional Recognition

  • Recommended in Intellectual Asset Management Patent 1000, 2016 - 2017
  • Ranked by Chambers USA, as "America's Leading Life Sciences; IP/Patent Litigation Lawyers," 2016 - 2017
  • Listed in The Best Lawyers in America: Patent Law, 2016 - 2018
  • Recognized by Managing Intellectual Property as an IP Star, 2013, 2014, 2016
  • Recognized by Managing Intellectual Property as a Top 250 Women in IP, 2013, 2014
  • Named by the Daily Journal as a "Top 25 Intellectual Property Portfolio Managers" in 2010, 2012

Professional Leadership

  • American Bar Association, Member

Related Employment

  • Howrey LLP, Palo Alto, CA, Partner, Intellectual Property
  • Rae-Venter Law Group, PC, Palo Alto, CA, Patent Agent, Intellectual Property
  • Metra Biosystems, Inc. , Development Director
  • Molecular Devices Corp., Senior Scientist
  • Liposome Technology, Inc., Senior Scientist
  • International Immunoassay Laboratories, Scientist

NEWS

PUBLICATIONS & PRESENTATIONS

RELATED INFORMATION

Areas of Focus

Bar and Court Admissions

  • California

  • U.S. Patent and Trademark Office

  • U.S. District Court for the Northern District of California

Education

  • Santa Clara University School of Law, J.D., 2000
  • University of California, Berkeley, Ph.D., Chemistry/Biochemistry, 1978
  • National Taiwan University, B.S., Chemistry, 1974

Highlights